Was the thrombotic risk of rofecoxib predictible from the French Pharmacovigilance Database before 30 September 2004?

European Journal of Clinical Pharmacology

Volumn 64, Issue 8, 2008, Pages 829-834

  Sommet, A ^a,b   Grolleau, S ^a   Bagheri, H ^a,b   Lapeyre Mestre, M ^a,b   Montastruc, J L ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Celecoxib; Pharmacovigilance; Rofecoxib; Thrombotic adverse drug reaction

Indexed keywords

CELECOXIB; ROFECOXIB;

ARTICLE; DATA BASE; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; HUMAN; PRIORITY JOURNAL; THROMBOSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; FRANCE; HUMANS; LACTONES; ODDS RATIO; PYRAZOLES; SULFONAMIDES; SULFONES; THROMBOSIS;

EID: 45849129389     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0497-3     Document Type: Article

References (33)

1. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307-314
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528
3. Silverstein FE, Faich G Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255
4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102
5. Clark DWJ, Laton D, Shakir AW (2004) Do some inhibitors of COX-2 increase the risk of thromboembolic events ? Drug Saf 27:427-456
6. Montastruc JL, Lapeyre-Mestre M, Gony M, Lugardon S, Bagheri H (2004) Coxibs, which real therapeutic advance? Recent pharmacoepidemiological data. Therapie 59:201-205
7. Arellano FM (2005) The withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf 14:213-217
8. Jüni P, Reichenbach S, Egger M (2005) COX 2 inhibitors, traditional NSAIDs and the heart. Br Med J 330:1342-1343
9. Nissen SE (2006) Adverse cardiovascular effects of rofecoxib. N Engl J Med 355:203-204
10. Graham D, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and bnon-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475-481
11. Strand V (2007) Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 370:2138-2151
12. Montastruc JL, Sommet A, Lacroix I, Olivier P, Durrieu G, Damase-Michel C, Lapeyre-Mestre M, Bagheri H (2006) Pharmacovigilance for evaluating adverse drug reactions: value, organization and methods. Joint Bone Spine 73:629-632
13. Stricker BH, Tijssen JG (1992) Serum sickness-like reactions to cefaclor. J Clin Epidemiol 45:1177-1184
14. Egberts AC, Meyboon RH, De Koning FH, Bakker A, Leufkens HG (1997) Nonpuerpueral lactation associated with antidepressant drug use. Br J Clin Pharmacol 44:277-281
15. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Begaud B (1998) Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/noncase study in the French pharmacovigilance system database. Br J Clin Pharmacol 44:513-518
16. Egberts AC, Meyboon RH, Van Puijenbroek EP (2002) Use of measures of disproportionality in pharmacovigilance: three dutch examples. Drug Saf 25:453-458
17. Lugardon S, Lapeyre-Mestre M, Montastruc JL, The French Network of Regional Pharmacovigilance Centres (2004) Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/noncase study from the French Pharmacovigilance Database. Eur J Clin Pharmacol 60:673-677
18. WHO (1992) International monitoring of adverse reactions to drugs: adverse reaction terminology. WHO collaborating Centre for International Drug Monitoring, Uppsala
19. Begaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugsActualization of the method used in France. Therapie 40:111-118
20. Van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW (2002) On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of underreporting on odds ratio. Stat Med 21:2027-2044
21. Wilson AM, Thabane L, Holbrook A (2004) Application of data mining data in pharmacovigilance. Br J Clin Pharmacol 57:127-134
22. Shakir SAW (2007) Thoughs on signal detection in Pharmacovigilance. Drug Saf 30:603-606
23. Hand DJ (2007) Principles of data mining. Drug Saf 30:621-622
24. Topol EJ (2004) Failing the public health - Rofecoxib, Merck, and the FDA. New Engl J Med 351:1707-1709
25. Mukherjee D, Nissen SE, Topol EL (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-957
26. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021-2029
27. Prescrire Rédaction (2002) Effets indésirables cardiovasculaires des coxibs. Rev Prescr 22:596-597
28. Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arrelano FM (2001) A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre Safety Database. Clin Ther 23:1478-1491
29. Layton D, Hughes K, Harris S, Shakir SAW (2003) Comparison of the incidence rates of thromboembolic events reported in patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 42:1342-1353
30. Layton D, Heeley E, Hughes K, Shakir SAW (2003) Comparison of the incidence rates of thromboembolic events reported in patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 42:1354-1364
31. Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA (2005) A comparison of reported gastrointestinal and thromboembolic events reported between rofecoxib and celecoxib using observational data. Drug Saf 28:803-816
32. Vu D, Murty M, McMorran M (2002) Selective COX-2 inhibitors: suspected cardiovascular/cerebrovascular adverse drug reactions. Can Adv Reactions News 2:1-3
33. Warmer TD, Mitchell JA (2008) COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371:270-273